Analyse and Visualise the Drug Development Cycle with Cortellis
Jinfo Blog
29th July 2014
Abstract
The new Cortellis life sciences platform from Thomson Reuters will be welcomed by many in the current "merger mania" environment in biopharma, explains reviewer Yulia Aspinall.
Item
The process of developing a new medicine is long and complex, with constant demands for different types of information from a variety of stakeholders in the process (scientific, clinical, legal and commercial, to name but a few).
Information professionals have a bewildering array of resources at their disposal to service this demand, both free and paid-for. Some of these provide access to a single type of information, for example Pubmed, and others to a variety of different types, such as Thomson Reuters' Cortellis.
Powered by Thomson Reuters Data
Cortellis is a new platform which integrates data from many well-known Thomson Reuters databases, including Thomson Pharma, Integrity and IDRAC and also offers users some new and unique analytical tools.
One of these - Virtual Merger - has a "wow factor" which, in my view, could on its own provide justification for purchasing the product.
Visualise a Virtual Merger
Virtual Merger, powered by TIBCO Spotfire, does exactly what the name suggests, providing a visual representation of a "virtual merger" of two companies of the user's choice.
The tool is accessed from the Analyze portlet on the Cortellis homepage; after entering the names of possible merging companies, users can view the visualised results on a pop-up page with intuitive visualisations and analytics.
The data can be displayed by:
- Development Funnels
- Drugs by Therapy Area
- Comparison by Action or Indication
- Comparison by Development Status
- Small Molecules vs Biologics
- Consensus Mechanisms
- Drug Financials
- Overviews.
There are also multiple filters available to use, such as Indications, Actions, Development Status, Drugs and Companies to narrow down the comparison according to the requirements.
Making M&A Decision-Making Quicker and Easier
In the current "merger mania" environment in biopharma industry, this tool will be welcomed by many in the company, especially by business development and senior management.
With the ability to analyse and visualise large amounts of data in minutes, and hence save potentially substantial amounts of work during the M&A decision-making process, the potential for time and workload savings is clear and could make the purchase of the platform a rational business decision.
Editor's Note
Cortellis has a host of interesting features. The full FreePint Report: Product Review of Cortellis is now available in PDF format, in a convenient package for reference and sharing, for those with a FreePint Subscription.
This article is part of the FreePint Topic Series: Next-Generation Competitive Intelligence which ran from May-June 2014. Registration provides a free copy of the FreePint Report: Buyer's Guide on Competitive Intelligence.
- Blog post title: Analyse and Visualise the Drug Development Cycle with Cortellis
- Link to this page
- View printable version
- Product Review of Cortellis (Value - Competitors, Development & Pricing)
Monday, 21st July 2014 - Product Review of Cortellis (Technology - Search, Outputs & Alerts, User Interface & Help)
Wednesday, 16th July 2014 - Product Review of Cortellis (Sources - Content & Coverage)
Monday, 14th July 2014 - Product Review of Cortellis (Introduction; Contact Details)
Thursday, 10th July 2014
- Concluding the FreePint Series: Next-Generation Competitive Intelligence
Monday, 7th July 2014 - A "Survival Kit" for Biopharma CI Professionals
Tuesday, 24th June 2014 - Competitive Intelligence, Discovery and the Pharma Industry
Friday, 20th June 2014
- FreePint Report: Product Review of Cortellis
Tuesday, 22nd July 2014
Discussing news and AI strategies with the Financial Times
Community session
21st November 2024
2025 strategic planning; evaluating research reports; The Financial Times, news and AI
Blog posting
5th November 2024
November 2024 Update
YouTube video
7th November 2024
- 2025 strategic planning; evaluating research reports; The Financial Times, news and AI
5th November 2024 - All recent Jinfo Subscription content
31st October 2024 - End-user training best practice research
24th October 2024
- Jinfo Community session (TBC) (Community) 12th December 2024
- Discussing news and AI strategies with the Financial Times (Community) 21st November 2024
- Asia-Pacific Community session (Community) 19th November 2024